Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Patoia, L.
Right arrow Articles by Marini, M. G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Patoia, L.
Right arrow Articles by Marini, M. G.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1996 British Society for Rheumatology

A 4-Week, Double-Blind, Parallel-Group Study to Compare the Gastrointestinal Effects of Meloxicam 7.5 mg, Meloxicam 15 mg, Piroxicam 20 mg and Placebo by Means of Faecal Blood Loss, Endoscopy and Symptom Evaluation in Healthy Volunteers

L. Patoia*, L. Santucci{dagger}, P. Furno*, M. S. Dionisi*, S. Dell'orso{ddagger}, M. Romagnoli§, A. Sattarinia and M. G. Marini{ddagger}

* Istituto di Medicina Interna e Scienze Oncologiche Perugia
{dagger} Istituto di Gastroenterologia e di Endoscopia Digestiva Perugia
§ Laboratorio Analisi Chimico-Cliniche e Microbiologiche Perugia
Servizio di Medicina Nucleare, Policlinico Monteluce, Università degli Studi di Perugia Perugia
{ddagger} Medical Department, Boehringer Ingelheim Italia Milano, Italy

Correspondence to: Correspondence to: Dr L. Patoia Istituto di Medicina Interna e Scienze Oncologiche, Policlinico Monteluce, Università degli Studi di Perugia, Perugia, Italy.


  Abstract

Meloxicam is a new non-steroidal anti-inflammatory drug (NSAID) which preferentially inhibits cyclooxygenase-2 (COX-2) over cyclooxygenase-1 (COX-1). Gastrointestinal (GI) tolerability of meloxicam 7.5 and 15 mg vs piroxicam 20 mg was evaluated in a 4-week, double-blind, parallel-group, placebo-controlled study in 51 healthy male volunteers, using a combination of oesphago-gastro-duodenal endoscopy, faecal blood loss measurement and symptom evaluation. Analysis of covariance found no significant difference in faecal blood loss between the groups. However, significantly higher bleeding was found with piroxicam 20 mg compared with placebo using a Student’s t-test on the weighted means. Endoscopy scores were significantly higher with piroxicam than with meloxicam 7.5 mg or placebo (P < 0.01). A significant difference from baseline was observed in the meloxicam 15 mg and piroxicam groups (P < 0.05), but not in the meloxicam 7.5 mg and placebo groups. Six piroxicam-treated volunteers were withdrawn following a poor endoscopic score, but no such withdrawals occurred in the meloxicam and placebo groups (P < 0.01). Meloxicam 7.5 mg caused less GI damage compared with piroxicam 20 mg when administered to healthy young volunteers for 28 days; a possible dose dependency effect in GI tolerability was also suggested for meloxicam 7.5 and 15 mg, in relation to endoscopic findings.

KEY WORDS: Meloxicam, Piroxicam, Gastrointestinal endoscopy, Faecal blood loss


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.